The Complete Spike Protein Detox Protocol: What Science Supports, What It Doesn't, and What to Watch

Since Dr. Peter McCullough published the first formal rationale for spike protein detoxification in 2023, the "base spike detox protocol" of nattokinase, bromelain, and curcumin has become the most widely discussed natural approach to addressing persistent spike protein. This article provides a comprehensive evidence review of the full protocol—what each component does, what the combined approach might achieve, and where the evidence genuinely stands.

The Problem: Spike Protein Persistence

Before evaluating solutions, the underlying problem must be established. Multiple studies have now confirmed that SARS-CoV-2 spike protein persists in human tissues long after acute infection resolves:

• Blood circulation: Spike protein and S1 subunit detected up to 12–14 months post-infection in ~65% of long COVID patients (Simoa assay; Swank et al., Clin Infect Dis, 2023)
• Gut tissue: Viral nucleoprotein and RNA detected 219+ days post-infection in intestinal epithelium (Zollner et al., IBD cohort)
• Brain: Spike protein accumulates in the skull-meninges-brain axis, persisting 12 months after viral clearance, with elevated neurodegeneration biomarkers in CSF (Rong et al., Cell Host Microbe, 2024)
• Multiple organs: Viral RNA detected in liver, kidney, stomach, intestine, brain, blood vessels, lung, breast, skin, and thyroid up to 4 months post-infection (317 tissue samples, 225 patients)
• Extracellular vesicles: Spike protein travels within exosomes, potentially evading immune detection and facilitating cell-to-cell transmission (e.g., astrocytes to neurons)

Critically, patients with detectable spike protein have a >50% likelihood of developing long COVID symptoms, with higher viral copy numbers correlating to more severe PASC symptoms.

The McCullough Base Spike Detoxification Protocol

Published in the Journal of American Physicians and Surgeons (Fall 2023), the protocol targets four mechanisms:

1. Proteolytic degradation of spike protein
2. Inhibition of inflammation from spike protein fragments in tissues
3. Dissolution of microthrombi (fibrin-resistant microclots)
4. Anticoagulation support

Core Protocol

Duration: 3–12 months or longer, guided by symptom resolution and clinical monitoring.

Extended Protocol (for severe or treatment-resistant cases)

Evidence Assessment: Component by Component

Nattokinase — Evidence Grade: B (Strong Preclinical, Limited Clinical)

• ✓ Direct spike protein degradation confirmed in vitro (Tanikawa 2022)
• ✓ Dose- and time-dependent mechanism validated
• ✓ Human fibrinolytic activity confirmed (D-dimer elevation at 2,000 FU)
• ✓ Blood pressure reduction in meta-analysis of 6 RCTs
• ✗ No human trial measuring spike protein clearance
• ✗ 3-year RCT showed no carotid artery benefit

Bromelain — Evidence Grade: B (Strong Preclinical, Limited Clinical)

• ✓ Triple-target action confirmed: ACE2 + TMPRSS2 + spike protein (Sagar 2021)
• ✓ Reduced live SARS-CoV-2 infection in cell cultures (p = 0.001)
• ✓ BromAc combination validated against Omicron in human tracheal aspirates (2025)
• ✓ Decades of safety data as anti-inflammatory supplement
• ✗ No human trial measuring spike protein clearance

NAC — Evidence Grade: B- (Solid Mechanistic, Moderate Preclinical)

• ✓ Cys391-Cys525 disulfide disruption confirmed by mass spectrometry
• ✓ 54.3% inhibition of SARS-CoV-2 replication in VeroE6 cells
• ✓ Synergy with bromelain (BromAc) validated against live virus
• ✓ Extensive clinical safety history (FDA-approved for acetaminophen overdose)
• ✗ Lower intrinsic antiviral potency compared to purpose-built thiol agents
• ✗ No human trial for spike protein clearance

Curcumin — Evidence Grade: C+ (Anti-inflammatory Support)

• ✓ RCTs show consistent hs-CRP reduction
• ✓ In silico evidence of spike protein binding inhibition (Omicron variant)
• ✓ Well-characterized NF-κB suppression
• ✗ Notoriously poor oral bioavailability (requires nano/liposomal formulation)
• ✗ No direct spike protein degradation activity

What No One Has Proven Yet

It is critical to be transparent about what has not been demonstrated:

1. No human RCT has tested the McCullough protocol (or any combination of these agents) against placebo for long COVID outcomes
2. No study has measured circulating spike protein levels before and after oral supplementation with any of these compounds
3. No dose-response relationship has been established in humans for spike protein clearance
4. No head-to-head comparison exists between the nattokinase/bromelain/curcumin triad and any other intervention

As of April 2026, ClinicalTrials.gov lists no completed or ongoing RCTs for nattokinase or bromelain in post-acute COVID-19. One planned trial examines curcumin with boswellia and vitamin C for long COVID.

Practical Guidance for Consumers

If You Decide to Try the Protocol:

1. Inform your physician, especially if on blood thinners, antiplatelet drugs, or immunosuppressants
2. Choose quality supplements: Look for FU specification on nattokinase, GDU specification on bromelain, and nano/liposomal or piperine-enhanced curcumin
3. Monitor for bleeding signs: Easy bruising, prolonged bleeding from cuts, blood in stool/urine
4. Track your symptoms: Keep a symptom diary to assess whether you're actually improving over 3–6 months
5. Get baseline labs: Consider D-dimer, hs-CRP, fibrinogen, CBC before starting and at 3-month intervals

When to Seek Medical Attention:

• Unusual bleeding or bruising
• Worsening cardiac symptoms (palpitations, chest pain)
• New neurological symptoms
• Allergic reactions (particularly to pineapple/bromelain or soy/nattokinase)

The Bottom Line

The McCullough base spike detoxification protocol is the most comprehensive evidence-based framework currently available for addressing persistent spike protein through oral supplementation. Each component has legitimate mechanistic support and acceptable safety profiles. However, the protocol remains empiric—it has not been validated in controlled clinical trials. The strongest endorsement it can receive today is that each component independently demonstrates relevant biological activity with decades of safety data, and no superior alternative with clinical proof exists.

The urgent need is for properly powered, double-blind, placebo-controlled trials. Until those exist, this protocol represents a reasonable risk-benefit calculation for symptomatic long COVID patients, undertaken with physician guidance.

This article is for informational purposes only and does not constitute medical advice.

References

1. McCullough PA, Wynn C, Procter BC. Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification. J Am Physicians Surg. 2023;28(3):90–93.
2. Shenoy V, et al. Clinical Approach to Post-acute Sequelae After COVID-19. Cureus. 2023;15(11):e49204.
3. Swank Z, et al. Persistent circulating spike antigen. Clin Infect Dis. 2023;76(3):e487–e490.
4. Rong Z, et al. Spike protein in skull-meninges-brain axis. Cell Host Microbe. 2024;32:1854–1869.
5. Tanikawa T, et al. Degradative Effect of Nattokinase on Spike Protein. Molecules. 2022;27(17):5405.
6. Sagar S, et al. Bromelain inhibits SARS-CoV-2 infection. Clin Transl Med. 2021;11(2):e281.
7. Pastore A, et al. NAC and SARS-CoV-2 spike protein. J Biomol Struct Dyn. 2024;42(10):5042–5052.
8. Silva L, et al. SARS-CoV-2 Spike Protein and Long COVID—Part 1. Biomedicines. 2025;13(5):1261.
9. BenDavid R, et al. Persistent SARS-CoV-2 reservoirs in chronic Long COVID. Vaccines. 2025;13(7):710.

Related Reading:

• Spike Protein Detox: Separating Evidence from Hype
• DFPP for Spike Protein Removal: What the Evidence Shows
• How to Choose Quality Nattokinase: Testing Guide